Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 95

1.

Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape.

Woo SR, Turnis ME, Goldberg MV, Bankoti J, Selby M, Nirschl CJ, Bettini ML, Gravano DM, Vogel P, Liu CL, Tangsombatvisit S, Grosso JF, Netto G, Smeltzer MP, Chaux A, Utz PJ, Workman CJ, Pardoll DM, Korman AJ, Drake CG, Vignali DA.

Cancer Res. 2012 Feb 15;72(4):917-27. doi: 10.1158/0008-5472.CAN-11-1620. Epub 2011 Dec 20.

PMID:
22186141
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors.

Duraiswamy J, Kaluza KM, Freeman GJ, Coukos G.

Cancer Res. 2013 Jun 15;73(12):3591-603. doi: 10.1158/0008-5472.CAN-12-4100. Epub 2013 Apr 30.

PMID:
23633484
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

LAG-3, TGF-β, and cell-intrinsic PD-1 inhibitory pathways contribute to CD8 but not CD4 T-cell tolerance induced by allogeneic BMT with anti-CD40L.

Lucas CL, Workman CJ, Beyaz S, LoCascio S, Zhao G, Vignali DA, Sykes M.

Blood. 2011 May 19;117(20):5532-40. doi: 10.1182/blood-2010-11-318675. Epub 2011 Mar 21.

PMID:
21422469
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Tumor-infiltrating regulatory T cells delineated by upregulation of PD-1 and inhibitory receptors.

Park HJ, Kusnadi A, Lee EJ, Kim WW, Cho BC, Lee IJ, Seong J, Ha SJ.

Cell Immunol. 2012 Jul-Aug;278(1-2):76-83. doi: 10.1016/j.cellimm.2012.07.001. Epub 2012 Jul 24.

PMID:
23121978
[PubMed - indexed for MEDLINE]
5.

Durable adoptive immunotherapy for leukemia produced by manipulation of multiple regulatory pathways of CD8+ T-cell tolerance.

Berrien-Elliott MM, Jackson SR, Meyer JM, Rouskey CJ, Nguyen TL, Yagita H, Greenberg PD, DiPaolo RJ, Teague RM.

Cancer Res. 2013 Jan 15;73(2):605-16. doi: 10.1158/0008-5472.CAN-12-2179. Epub 2012 Nov 27.

PMID:
23188506
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Analysis of the role of negative T cell costimulatory pathways in CD4 and CD8 T cell-mediated alloimmune responses in vivo.

Ito T, Ueno T, Clarkson MR, Yuan X, Jurewicz MM, Yagita H, Azuma M, Sharpe AH, Auchincloss H Jr, Sayegh MH, Najafian N.

J Immunol. 2005 Jun 1;174(11):6648-56.

PMID:
15905503
[PubMed - indexed for MEDLINE]
Free Article
7.

Effects of interferon-α-transduced tumor cell vaccines and blockade of programmed cell death-1 on the growth of established tumors.

Omori R, Eguchi J, Hiroishi K, Ishii S, Hiraide A, Sakaki M, Doi H, Kajiwara A, Ito T, Kogo M, Imawari M.

Cancer Gene Ther. 2012 Sep;19(9):637-43. doi: 10.1038/cgt.2012.42. Epub 2012 Jul 13.

PMID:
22790963
[PubMed - indexed for MEDLINE]
8.

Simultaneous blockade of multiple immune system inhibitory checkpoints enhances antitumor activity mediated by interleukin-15 in a murine metastatic colon carcinoma model.

Yu P, Steel JC, Zhang M, Morris JC, Waldmann TA.

Clin Cancer Res. 2010 Dec 15;16(24):6019-28. doi: 10.1158/1078-0432.CCR-10-1966. Epub 2010 Oct 5.

PMID:
20924130
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer.

Matsuzaki J, Gnjatic S, Mhawech-Fauceglia P, Beck A, Miller A, Tsuji T, Eppolito C, Qian F, Lele S, Shrikant P, Old LJ, Odunsi K.

Proc Natl Acad Sci U S A. 2010 Apr 27;107(17):7875-80. doi: 10.1073/pnas.1003345107. Epub 2010 Apr 12.

PMID:
20385810
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Enhanced tumor eradication by combining CTLA-4 or PD-1 blockade with CpG therapy.

Mangsbo SM, Sandin LC, Anger K, Korman AJ, Loskog A, Tötterman TH.

J Immunother. 2010 Apr;33(3):225-35. doi: 10.1097/CJI.0b013e3181c01fcb.

PMID:
20445343
[PubMed - indexed for MEDLINE]
11.

B7-DC-Ig enhances vaccine effect by a novel mechanism dependent on PD-1 expression level on T cell subsets.

Mkrtichyan M, Najjar YG, Raulfs EC, Liu L, Langerman S, Guittard G, Ozbun L, Khleif SN.

J Immunol. 2012 Sep 1;189(5):2338-47. doi: 10.4049/jimmunol.1103085. Epub 2012 Jul 25.

PMID:
22837483
[PubMed - indexed for MEDLINE]
Free Article
12.

Tumor-infiltrating programmed death receptor-1+ dendritic cells mediate immune suppression in ovarian cancer.

Krempski J, Karyampudi L, Behrens MD, Erskine CL, Hartmann L, Dong H, Goode EL, Kalli KR, Knutson KL.

J Immunol. 2011 Jun 15;186(12):6905-13. doi: 10.4049/jimmunol.1100274. Epub 2011 May 6.

PMID:
21551365
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Anti-PD-1 synergizes with cyclophosphamide to induce potent anti-tumor vaccine effects through novel mechanisms.

Mkrtichyan M, Najjar YG, Raulfs EC, Abdalla MY, Samara R, Rotem-Yehudar R, Cook L, Khleif SN.

Eur J Immunol. 2011 Oct;41(10):2977-86. doi: 10.1002/eji.201141639. Epub 2011 Aug 17.

PMID:
21710477
[PubMed - indexed for MEDLINE]
14.

Blockade of programmed death-1 pathway rescues the effector function of tumor-infiltrating T cells and enhances the antitumor efficacy of lentivector immunization.

Zhou Q, Xiao H, Liu Y, Peng Y, Hong Y, Yagita H, Chandler P, Munn DH, Mellor A, Fu N, He Y.

J Immunol. 2010 Nov 1;185(9):5082-92. doi: 10.4049/jimmunol.1001821. Epub 2010 Oct 6.

PMID:
20926790
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Functionally distinct LAG-3 and PD-1 subsets on activated and chronically stimulated CD8 T cells.

Grosso JF, Goldberg MV, Getnet D, Bruno TC, Yen HR, Pyle KJ, Hipkiss E, Vignali DA, Pardoll DM, Drake CG.

J Immunol. 2009 Jun 1;182(11):6659-69. doi: 10.4049/jimmunol.0804211.

PMID:
19454660
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade.

Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N.

Proc Natl Acad Sci U S A. 2002 Sep 17;99(19):12293-7. Epub 2002 Sep 6.

PMID:
12218188
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Simultaneous inhibition of two regulatory T-cell subsets enhanced Interleukin-15 efficacy in a prostate tumor model.

Yu P, Steel JC, Zhang M, Morris JC, Waitz R, Fasso M, Allison JP, Waldmann TA.

Proc Natl Acad Sci U S A. 2012 Apr 17;109(16):6187-92. doi: 10.1073/pnas.1203479109. Epub 2012 Apr 2.

PMID:
22474386
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems.

Grosso JF, Kelleher CC, Harris TJ, Maris CH, Hipkiss EL, De Marzo A, Anders R, Netto G, Getnet D, Bruno TC, Goldberg MV, Pardoll DM, Drake CG.

J Clin Invest. 2007 Nov;117(11):3383-92.

PMID:
17932562
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Two distinct mechanisms of augmented antitumor activity by modulation of immunostimulatory/inhibitory signals.

Mitsui J, Nishikawa H, Muraoka D, Wang L, Noguchi T, Sato E, Kondo S, Allison JP, Sakaguchi S, Old LJ, Kato T, Shiku H.

Clin Cancer Res. 2010 May 15;16(10):2781-91. doi: 10.1158/1078-0432.CCR-09-3243. Epub 2010 May 11.

PMID:
20460483
[PubMed - indexed for MEDLINE]
Free Article
20.

At the bench: preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy.

Intlekofer AM, Thompson CB.

J Leukoc Biol. 2013 Jul;94(1):25-39. doi: 10.1189/jlb.1212621. Epub 2013 Apr 26. Review.

PMID:
23625198
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk